Harnessing the power of the human microbiome to prevent and treat disease.
We are leveraging the untapped potential of the human microbiome to develop novel medicinal products that restore health and prevent disease, with a specific focus on drug-resistant bacterial infections.
The human microbiome is composed of over a trillion microorganisms that play a key role in many critical bodily functions. Many believe that the microbiome has substantial untapped therapeutic potential. At EnteroBiotix, we are unlocking this potential through novel approaches to treat disease and improve human health.
We are leveraging our MHRA-licensed platform capabilities, know-how and proprietary technology to advance three core product portfolios that build on the science of a medical treatment called faecal microbiota transplantation (FMT). Our initial focus is on antibiotic-resistant bacteria.
If you’re a patient suffering from an infection caused by C.difficile or a different type of microbiome mediated condition, you may be able to access our products through your doctor and our compassionate use programme.
We have rigorously screened and ready-to-use microbial products manufactured under a license from the MHRA. These products are available to order on a named patient basis for use in FMT.